Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia.
about
Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission.Targeting immune suppressing myeloid-derived suppressor cells in oncology.Dendritic cells from patients with chronic myeloid leukemia: functional and phenotypic features.Hepatitis B reactivation in chronic myeloid leukemia patients receiving tyrosine kinase inhibitor.Development and dynamics of robust T-cell responses to CML under imatinib treatmentThe biological basis for immunotherapy in patients with chronic myelogenous leukemia.Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.Phenotype of NK-Like CD8(+) T Cells with Innate Features in Humans and Their Relevance in Cancer Diseases.Role of tyrosine kinase inhibitors in tumor immunology.Small-molecule protein kinase inhibitors and their effects on the immune system: implications for cancer treatment.Immunomodulatory effects of anti-angiogenic drugs.Immunology of chronic myeloid leukemia: current concepts and future goals.Hepatitis B reactivation in patients receiving targeted therapies.Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis.Dendritic cells become BCR-ABL negative in chronic myeloid leukaemia patients successfully treated with imatinib.Imatinib inhibits the activation and proliferation of normal T lymphocytes in vitro.Molecular regulation of dendritic cell development and function in homeostasis, inflammation, and cancer.pDCs in lung and skin fibrosis in a bleomycin-induced model and patients with systemic sclerosis.
P2860
Q33593877-B43371B2-B113-4F05-9073-85CAE3622464Q34082067-82B398D7-4FBB-43CC-A60C-7A10C3D79F4EQ36194635-6F99EFE1-7AA5-4499-A6B8-D03B4F9B6067Q36654518-9C1661EF-C96B-4308-92A2-2113B44A90C5Q36677315-04D7ECC2-41F1-44E0-8CB3-41B4C4EA24DBQ37428671-268B41C3-1079-4B13-B76E-D4FFE0857288Q37625756-A37FA3C0-5D8B-43D6-AED1-32041B1B4394Q37721209-26913011-169E-4C82-8B40-56109C85A6BFQ37822748-F6374FD4-F8F4-48C9-AAC0-16B5F157BD78Q37842326-CDB7B6F2-B57E-468F-AA43-2FFBD3E7E999Q37847051-EED65205-1373-4681-AA8A-0938E86B9DEFQ38366539-74153FCA-F046-4A71-A4CB-8213E02A6A5AQ39293427-03B8278D-1A4D-4E61-9BBA-EB434BB799F4Q42103971-A1316035-EADE-4F8A-9C54-789743198988Q44795662-E665C428-427E-4CAF-B0AB-A7A75E17812CQ44931488-BD9E9D77-C840-4DA5-96B5-3772D8872CE7Q52726024-B4755F5E-0B46-4D12-84D1-63807FE48910Q55294849-29B6DA03-AF87-438D-B02E-1224847DD710
P2860
Imatinib and plasmacytoid dendritic cell function in patients with chronic myeloid leukemia.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
Imatinib and plasmacytoid dend ...... with chronic myeloid leukemia.
@en
Imatinib and plasmacytoid dend ...... with chronic myeloid leukemia.
@nl
type
label
Imatinib and plasmacytoid dend ...... with chronic myeloid leukemia.
@en
Imatinib and plasmacytoid dend ...... with chronic myeloid leukemia.
@nl
prefLabel
Imatinib and plasmacytoid dend ...... with chronic myeloid leukemia.
@en
Imatinib and plasmacytoid dend ...... with chronic myeloid leukemia.
@nl
P2093
P921
P1433
P1476
Imatinib and plasmacytoid dend ...... with chronic myeloid leukemia.
@en
P2093
Béatrice Gaugler
Daniel Isnardon
Daniel Olive
Didier Blaise
Eric Jourdan
Ghandi Damaj
Mohamad Mohty
Naira Ben Mami
Norbert Vey
P304
P356
10.1182/BLOOD-2003-09-3220
P407
P577
2004-01-08T00:00:00Z